Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tricor noninfringement ruling upheld

Executive Summary

U.S. federal appeals court upholds Chicago district court judge's noninfringement ruling on Teva's generic version of Abbott's Tricor (fenofibrate) capsules. Teva began marketing a generic of the cholesterol agent after the lower court's March 2002 ruling. In response, Abbott launched a campaign to switch Tricor capsule users to tablets (1"The Pink Sheet" Sept. 30, 2002, p. 27)...

You may also be interested in...



CML Healthcare fenofibrate “approvable”

CML Healthcare's NDA for a "novel formulation" of fenofibrate (Abbott's triglyceride-lowering agent TriCor) deemed "approvable" by FDA Jan. 13, company says. The agency requested additional details relating to chemistry, manufacturing and labeling for the NDA which was filed in December 2002. In March 2003, Fournier, the French company that licenses TriCor to Abbott, filed suit against CML Healthcare in Puerto Rico federal court. A U.S. federal appeals court recently upheld Chicago federal judge's noninfringement ruling on Teva's generic version of the drug (1"The Pink Sheet" March 31, 2003, In Brief)...

Bear Stearns Healthcare Conference, In Brief

Abbott D2E7 advisory committee?: Abbott has "not heard anything at all" about a possible early December FDA advisory committee meeting for its anti-TNF monoclonal antibody D2E7 (adalimumab), CFO Thomas Freyman told Bear Stearns healthcare conference in New York City. Abbott does not believe "having a panel or not having a panel is going to impact our timing at all in terms of product launch." In a separate Bear Stearns presentation, Enbrel marketer Amgen Investor Relations Director Anna McDermott-Vitak said she "would be surprised" if D2E7 was not the subject of an advisory committee meeting. Abbott submitted a BLA for D2E7 in rheumatoid arthritis April 2; the company expects to launch adalimumab in the first half of 2003...

Teva CEO Schultz: ‘Proof Is In The Pudding’ For US Biosimilars

Teva CEO Kåre Schultz believes his prediction is coming true for the Truxima biosimilar in-licensed from Celltrion, as he gave the latest update on Teva’s efforts to settle significant legal issues around the US opioid crisis.

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel